Indivior Pharmaceuticals (INDV) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Indivior Pharmaceuticals (INDV) has outperformed Organon (OGN) over the past year, gaining 47.3% versus a gain of 34.3%. Over five years, INDV leads with a +123.7% price change compared with -60.6% for OGN. Indivior Pharmaceuticals is the larger company by market cap ($4.23 billion vs $3.63 billion), about 1.2 times the size.
On valuation, Organon trades at a lower forward P/E (3.8x vs 7.3x for Indivior Pharmaceuticals). Organon pays a dividend yielding 0.58%, while Indivior Pharmaceuticals does not currently pay one. Indivior Pharmaceuticals converts more of its revenue into profit, with a net margin of 16.9% versus 3.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDV | OGN |
|---|---|---|
| Share price | $35.83 | $13.81 |
| Market cap | $4.23B | $3.63B |
| 1-day change | +1.07% | +0.44% |
| YTD return | -1.20% | +91.77% |
| 1-year return | +47.28% | +34.28% |
| 5-year return | +123.66% | -60.59% |
| P/E ratio (TTM) | 12.84 | 17.71 |
| Forward P/E | 7.34 | 3.82 |
| EPS (TTM) | $2.79 | $0.78 |
| Dividend yield | 0.00% | 0.58% |
| Annual dividend | $0.00 | $0.08 |
| Revenue (latest FY) | $1.24B | $6.22B |
| Revenue growth (YoY) | +4.29% | -2.92% |
| Net income (latest FY) | $210.00M | $187.00M |
| Gross margin | 80.23% | 53.30% |
| Operating margin | 21.15% | — |
| Net margin | 16.95% | 3.01% |
| 52-week high | $42.81 | $13.83 |
| 52-week low | $22.95 | $5.69 |
| Distance from 52-week high | -16.30% | -0.14% |
| Analyst consensus | none | none |
| Avg. price target upside | +36.76% | -18.54% |
| Average volume | 2.07M | 2.66M |
| Shares outstanding | 118.03M | 262.61M |
| Employees | 827 | 10,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INDV has outperformed OGN by 13.0 percentage points over the past year.
- Organon trades at a higher earnings multiple (17.7x vs 12.8x trailing P/E).
- Indivior Pharmaceuticals is more profitable, keeping 16.9 cents of every revenue dollar as net income versus 3.0 cents for Organon.
- Indivior Pharmaceuticals grew revenue faster in its latest fiscal year (+4.29% vs -2.92%).
About Indivior Pharmaceuticals
INDV stock →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
INDV vs OGN FAQ
Which is bigger, Indivior Pharmaceuticals or Organon?
Indivior Pharmaceuticals (INDV) is larger, with a market capitalization of $4.23B compared with $3.63B for Organon (OGN).
Which stock has performed better over the past year, INDV or OGN?
INDV returned +47.28% over the past 12 months, compared with +34.28% for OGN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, INDV or OGN?
INDV has the lower trailing P/E at 12.8, versus 17.7 for OGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Indivior Pharmaceuticals or Organon?
Organon pays a dividend yielding 0.58%, while Indivior Pharmaceuticals does not currently pay a regular dividend.
Are Indivior Pharmaceuticals and Organon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.